We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

Novo Nordisk (NYSE:NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N. Overall, NVO ranks 6th on our list of firms that took a hit on Friday ...

The firm attributes its lower revenue projections to conservative estimates for Levemir and Victoza, two of Novo Nordisk's products. With an impressive gross profit margin of 84.66% and a P/E ...

Novo Nordisk (NYSE:NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N. Overall, NVO ranks 6th on our list of firms that took a hit on ...

Novo Nordisk (NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N.

Novo and competitors such as Sanofi and Eli ... and which now outsells its biggest insulin product, Levemir, which saw its revenues decline in 2016. FDA insistence that companies must undertake ...